Immune Specific and Tumor-Dependent mRNA Vaccines for Cancer Immunotherapy: Reprogramming Clinical Translation into Tumor Editing Therapy

• Główni autorzy: Theodora Katopodi (Autor), Savvas Petanidis (Autor), Eirini Grigoriadou (Autor), Doxakis Anestakis (Autor), Charalampos Charalampidis (Autor), Ioanna Chatziprodromidou (Autor), George Floros (Autor), Panagiotis Eskitzis (Autor), Paul Zarogoulidis (Autor), Charilaos Koulouris (Autor), Christina Sevva (Autor), Konstantinos Papadopoulos (Autor), Panagiota Roulia (Autor), Stylianos Mantalovas (Autor), Marios Dagher (Autor), Alexandros Vasileios Karakousis (Autor), Nikolaos Varsamis (Autor), Konstantinos Vlassopoulos (Autor), Vasiliki Theodorou (Autor), Chrysi Maria Mystakidou (Autor), Nikolaos Iason Katsios (Autor), Konstantinos Farmakis (Autor), Christoforos Kosmidis (Autor)
• Format: Książka
• Wydane: MDPI AG, 2024-03-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Extensive research into mRNA vaccines for cancer therapy in preclinical and clinical trials has prepared the ground for the quick development of immune-specific mRNA vaccines during the COVID-19 pandemic. Therapeutic cancer vaccines based on mRNA are well tolerated, and are an attractive choice for...